Tiziana Life Sciences Reports Positive Phase 2a Clinical Data Exhibiting Positive Clinical Activity with Milciclib Monotherapy in Advanced Sorafenib-refractory or -intolerant Patients with Unresectable or Metastatic Hepatocellular Carcinoma

The clinical activity assessment in evaluable patients was based on the investigators review using the modified Response Evaluation Criteria in Solid Tumors (mRECIST).